Why the study?
Do thiazolidinediones cause or exacerbate congestive heart failure in patients with diabetes?
Do thiazolidinediones cause or exacerbate congestive heart failure in patients with diabetes?
Thiazolidinediones cause fluid retention but current evidence does not link this to worsening heart function, allowing cautious use in patients with mild heart failure.
May permit cautious use in mild HF; leaves open need for randomized cardiac safety confirmation.
Concern has been raised about whether the fluid retention caused by thiazolidinediones (TZDs, ie, rosiglitazone and pioglitazone) can cause or exacerbate congestive heart failure. Although fluid retention is a worrisome side effect of TZDs, current evidence does not link fluid retention caused by TZDs with worsening heart function. TZDs have many benefits for patients with diabetes and can even be used cautiously in patients with mild heart failure, with careful monitoring of volume status.
No takes yet. Share an insight, caveat, or question.
W.H. Wilson Tang (2006) studied this question.